• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

    7/25/24 8:00:00 AM ET
    $EXAS
    $PODD
    Medical Specialities
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $EXAS alert in real time by email

    Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients

    Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale

    Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing.

    The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also included participation from new investors, including Catalio Capital Management, LP, HealthCor Family Office, Montreux Growth Partners, and INTAI Technology Corp.

    "We are grateful for the continued support of our existing investors and welcome our new investors who share our vision for leadership in stroke and vascular thrombectomy," said Fred Khosravi, Chairman and CEO of Imperative Care. "This latest financing fuels our hypergrowth strategy as we work to make better care accessible to more patients. We will continue to invest in novel technologies and clinical evidence to measure the impact of these technologies on patient outcomes."

    "As investors in Imperative Care since the company's Series C financing in December 2019, we have been impressed with the dramatic progress the company has made on many fronts, including treating more than 45,000 patients with life-saving technologies," said Ally Bridge founder and CEO Frank Yu, who has also served as a Director on the Imperative Care Board since 2019. "We are excited to support the next stage of Imperative Care's success, as the company strengthens its position for treating ischemic stroke and prepares to make a major contribution to the treatment of peripheral vascular disease."

    After the initial closing and subject to the discretion of the Company, there may be additional closings of this Series E financing, raising up to $150 million in total.

    Appointment of Shacey Petrovic to Vice Chair, Board of Directors

    The company also announced the appointment of Shacey Petrovic to the newly created position of Vice Chair of its Board of Directors. Petrovic joined the Imperative Care Board in 2023. In the role of Vice Chair, Petrovic will focus on strategies to scale the company with the goal of bringing life-changing technologies to more patients suffering from stroke and other devastating vascular diseases.

    Petrovic also serves on the Boards of Exact Sciences (NASDAQ:EXAS), Ambu A/S (OTC US: AMBBY) and Axena Health. Previously, Petrovic served on the board and was President and CEO of Insulet Corporation (NASDAQ:PODD), a diabetes technology company. Under her leadership, Insulet grew to serve hundreds of thousands of people with diabetes across the globe.

    "It has been a privilege to benefit from Shacey's business acumen and strategic mastery as we position Imperative Care for long term success and scale," Khosravi said. "On behalf of our Board of Directors, I would like to congratulate Shacey on her appointment to Vice Chair as we continue to build the thrombectomy company of the future with the patient at the center."

    "I am excited to step into this new leadership role as Imperative Care accelerates its work to deliver impactful innovations to patients at the most tenuous moments of their lives," said Petrovic. "My experience serving on the Imperative Care Board has been quite inspirational as the company engineers solutions to some of the greatest challenges in medicine through medtech and digital health innovations."

    About Imperative Care, Inc.

    Imperative Care is a commercial-stage medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company is focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif. https://imperativecare.com

    Legal Disclaimer / Forward-Looking Statements

    This press release is not an offer to sell securities or a solicitation of an offer to buy any securities, and may not be relied upon in connection with the purchase or sale of any company security. This release may contain forward-looking statements regarding plans for future financing, projected business performance, future innovations and improvement of patient outcomes. Such statements are forward-looking statements and there can be no assurance that the results stated or implied by these forward-looking statements will actually be realized or achieved by the company. Forward-looking statements may be based on management assumptions that could prove to be wrong. The company's predictions may not be realized for a variety of reasons as the company's business is subject to substantial risks and potential events beyond its control that could cause material differences between predicted and actual results.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240725822876/en/

    Get the next $EXAS alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $EXAS
    $PODD

    CompanyDatePrice TargetRatingAnalyst
    Insulet Corporation
    $PODD
    6/16/2025$365.00Buy
    Truist
    Insulet Corporation
    $PODD
    5/30/2025$380.00Buy
    Goldman
    Insulet Corporation
    $PODD
    5/13/2025$350.00Peer Perform → Outperform
    Wolfe Research
    Insulet Corporation
    $PODD
    4/29/2025Outperform → Peer Perform
    Wolfe Research
    Exact Sciences Corporation
    $EXAS
    4/10/2025$60.00Outperform
    Mizuho
    Exact Sciences Corporation
    $EXAS
    3/13/2025$52.00Sector Perform
    RBC Capital Mkts
    Insulet Corporation
    $PODD
    3/6/2025$340.00Outperform
    RBC Capital Mkts
    Exact Sciences Corporation
    $EXAS
    1/23/2025$70.00Overweight
    Barclays
    More analyst ratings

    $EXAS
    $PODD
    SEC Filings

    See more
    • SEC Form S-8 POS filed by Exact Sciences Corporation

      S-8 POS - EXACT SCIENCES CORP (0001124140) (Filer)

      7/11/25 4:06:24 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by Exact Sciences Corporation

      S-8 - EXACT SCIENCES CORP (0001124140) (Filer)

      7/11/25 4:02:07 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • SEC Form 11-K filed by Exact Sciences Corporation

      11-K - EXACT SCIENCES CORP (0001124140) (Filer)

      6/24/25 4:01:22 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Insulet with a new price target

      Truist initiated coverage of Insulet with a rating of Buy and set a new price target of $365.00

      6/16/25 7:50:27 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Insulet with a new price target

      Goldman initiated coverage of Insulet with a rating of Buy and set a new price target of $380.00

      5/30/25 8:41:35 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet upgraded by Wolfe Research with a new price target

      Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $350.00

      5/13/25 8:51:02 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $EXAS
    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Conroy Kevin T bought $1,001,325 worth of shares (19,500 units at $51.35), increasing direct ownership by 2% to 1,074,191 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      11/13/24 12:56:28 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • EVP, CFO & Treasurer Chadwick Ana Maria bought $20,600 worth of shares (100 units at $206.00), increasing direct ownership by 0.76% to 13,314 units (SEC Form 4)

      4 - INSULET CORP (0001145197) (Issuer)

      8/29/24 4:17:26 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Singh Prem bought $169 worth of shares (1 units at $168.92), increasing direct ownership by 0.02% to 4,032 units

      4 - INSULET CORP (0001145197) (Issuer)

      9/21/23 4:48:23 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $EXAS
    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Doyle James Edward was granted 5,398 shares, increasing direct ownership by 10% to 61,447 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      6/16/25 5:30:22 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Director Popovits Kimberly J was granted 9,994 shares, increasing direct ownership by 156% to 16,381 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      6/16/25 5:30:15 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Director Barber Michael J was granted 7,197 shares, increasing direct ownership by 121% to 13,136 units (SEC Form 4)

      4 - EXACT SCIENCES CORP (0001124140) (Issuer)

      6/16/25 5:30:20 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

      Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) test has received Medicare coverage through the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostic Services Program (MolDX) for serial use in patients with stage II, III and resectable stage IV colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings over a five-year period. The final LCD can be found here, and the billing and coding article here, from CMS. This marks a significant milestone in the company's mission to transform cancer treatment through earlier detection and more personalize

      7/9/25 6:00:00 AM ET
      $EXAS
      Medical Specialities
      Health Care
    • Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2

      7/8/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions

      Presentations and panel discussions to provide deeper dives into the clinical outcomes from Insulet's groundbreaking SECURE-T2D and RADIANT trials Real-world evidence around glycemic outcomes from more than 23,000 people with type 2 diabetes using Omnipod 5 in the United States will also be shared Booth activities include podcasts, hands-on demonstrations led by clinical experts, and immersive experiences, including a comic book featuring a new hero with type 1 diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diab

      6/19/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care

    $EXAS
    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Exact Sciences Corporation

      SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

      11/13/24 2:58:53 PM ET
      $EXAS
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Insulet Corporation

      SC 13G/A - INSULET CORP (0001145197) (Subject)

      11/12/24 12:53:28 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

      SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

      11/8/24 10:52:39 AM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    $PODD
    Financials

    Live finance-specific insights

    See more
    • Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2025 on August 7, 2025, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929) 203-2

      7/8/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)

      Raising Full Year Revenue and Gross Margin Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months ended March 31, 2025. "Our first quarter results showcase the strong execution and dedication of the Insulet team, who has continued to expand the reach of Omnipod 5 technology to people living with diabetes globally. As Insulet's new President and CEO, I see a path to scale the Company from an emerging diabetes leader to a durable growth engine, driving an even greater impact for our partners, stakeholders, and most importantly, our P

      5/8/25 4:01:00 PM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • Exact Sciences Announces First-Quarter 2025 Results

      First quarter highlights Delivered total first quarter revenue of $707 million, an increase of 11% on a reported and core revenue basis, including Screening revenue of $540 million and Precision Oncology revenue of $167 million Raised full-year 2025 revenue and adjusted EBITDA guidance midpoints by $40 million and $15 million, respectively Launched the Cologuard Plus™ test, the company's next-generation colon cancer screening test Presented data in the Journal of Surgical Oncology demonstrating the clinical strength of the Oncodetect™ test, the company's molecular residual disease ("MRD") and recurrence monitoring test Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of canc

      5/1/25 4:05:00 PM ET
      $EXAS
      Medical Specialities
      Health Care

    $EXAS
    $PODD
    Leadership Updates

    Live Leadership Updates

    See more
    • Insulet Appoints Ashley McEvoy President and CEO

      Expects to Exceed First Quarter Revenue Guidance and Raise Full Year 2025 Guidance Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Board of Directors has appointed Ashley McEvoy President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Ms. McEvoy succeeds Jim Hollingshead, who has agreed with Insulet's Board of Directors that his employment with the Company will cease effective as of April 28, 2025, and resigned from the Insulet Board of Directors. The Insulet Board and Mr. Hollingshead mutually agreed that now is the rig

      4/28/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care
    • SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

      SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ:SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. Marcus Wilson also informed the Company that, as part of that same

      3/19/25 4:10:00 PM ET
      $EXAS
      $QTRX
      $SERA
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Insulet to Host Investor Day on June 5, 2025

      Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, will host an Investor Day at the Company's global headquarters in Acton, Massachusetts on Thursday, June 5, 2025. Presentations will be led by Jim Hollingshead, President and CEO, members of the Executive Leadership Team, and independent experts. The agenda will include a comprehensive overview of the Company's leading Omnipod® 5 platform, strategic priorities, market opportunities, growth drivers, innovation roadmap, and financial outlook. Presentations will begin at 10:00 a.m. (ET) and conclude at approximately 1:30 p.m. (ET). The Company

      3/11/25 6:00:00 AM ET
      $PODD
      Medical/Dental Instruments
      Health Care